Barclays analyst Christine Cho maintains Array Technologies (NASDAQ:ARRY) with a Overweight and raises the price target from $20 to $22.
Gain Therapeutics Announces Preclinical Data Showing Restoration Of Enzymatic Function With Novel Allosteric Regulators In GM1 Gangliosidosis Model
Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in collaboration with Institute for Research in
